You are here: Home Newsroom News Boots supports study to use everyday shopping data to spot early signs of cancer

Boots supports study to use everyday shopping data to spot early signs of cancer

02 February 2026
News Healthcare

Researchers at Imperial College London are launching a major new study to explore whether loyalty card data from major UK retailers like Boots could help reveal the early warning signs of cancer.

As one of the country’s largest and longest‑standing loyalty programmes, Boots Advantage Card is playing an important role in this research.

Cancer Loyalty Card Study (CLOCS-2) is the second study of this kind, and will analyse shopping patterns from almost 3,000 volunteers, comparing the purchase history of people diagnosed with cancer with that of healthy participants.

The hope is this data will reveal subtle trends which could be used to flag the early signs of disease and ultimately lead to much earlier medical interventions for a variety of cancers.

Earlier work using data from Boots Advantage Card showed that changes in buying over‑the‑counter pain or indigestion medicines could appear months before an ovarian cancer diagnosis. Building on that insight, the new study will expand its scope of research to investigate 10 cancer types, including bowel, ovarian, pancreatic, liver, stomach and oesophageal cancers.

Many of these cancers start with symptoms people often self‑manage first including bloating, fatigue or indigestion. Researchers hope that spotting subtle shifts in what people buy could one day act as a nudge to seek medical advice sooner, potentially improving the chances of early detection.

“This study ultimately has the potential to revolutionise how we can use everyday data to understand and improve people’s health,” said Professor James Flanagan from Imperial’s Department of Surgery and Cancer, who is leading the study. “We’re excited to build on the success of our first CLOCS study and to see if looking back at people’s shopping history can give us clues to the way different conditions start to appear.”

If successful, the researchers hope to launch an intervention study to monitor the purchasing data from consenting healthy individuals for specific ‘triggers’. This could eventually pave the way for a potential digital alert system that prompts shoppers to seek medical advice based on their specific purchasing behaviour.

Marc Donovan, Healthcare Development Director at Boots, said: “CLOCS-2 is an inspiring example of what’s possible when retailers, researchers and charities work together to connect different data points. Over a quarter of the UK population has a Boots Advantage Card, and this study represents the potential for everyday shopping data, when used responsibly, to be a powerful tool in helping customers spot and act on early healthcare warning signs.”  

News

What’s new at Boots? Find out the latest updates from the UK’s largest pharmacy-led health and beauty chain – from new products and services to important business developments.

xx

Features

Take a closer look at our team members and the work they do, learn more about our corporate social responsibility initiatives and see how we work behind the scenes.

xx

About Boots: 

Boots is the UK’s leading health, wellness and beauty retailer with over 52,000 team members and over 1,800 stores, ranging from local community pharmacies to large destination health and beauty destinations.*  

Boots serves its customers and patients for life as the leading provider of healthcare on the high street and the UK’s number one beauty destination. It offers an unrivalled depth and breadth of products, which incorporates its extensive own brand range and innovative portfolio of brands, including No7, the UK’s No1 skincare brand, Soap & Glory, Liz Earle Beauty and Sleek MakeUP.    

*Figures accurate as of 31 May 2025